Evidence map›Paper›PMID 33722885›Full record

ArticleAntimicrobial agents and chemotherapy2021

Cefepime Population Pharmacokinetics and Target Attainment in Critically Ill Patients on Continuous Renal Replacement Therapy.

Mohammad H Al-Shaer, Carolyn D Philpott, Christopher A Droege, Joshua D Courter, Daniel P Healy, Molly E Droege, Neil E Ernst, Eric W Mueller, Charles A Peloquin

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mohammad H Al-ShaerInfectious Disease Pharmacokinetics Laboratory, Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.ORCID 0000-0003-1432-5175
Carolyn D PhilpottUC Health - University of Cincinnati Medical Center, Department of Pharmacy Services, Cincinnati, Ohio, USA carolyn.philpott@uchealth.com.ORCID 0000-0002-0962-1001
Christopher A DroegeUC Health - University of Cincinnati Medical Center, Department of Pharmacy Services, Cincinnati, Ohio, USA.
Joshua D CourterCincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Daniel P HealyUniversity of Cincinnati James L. Winkle College of Pharmacy, Cincinnati, Ohio, USA.
Molly E DroegeUC Health - University of Cincinnati Medical Center, Department of Pharmacy Services, Cincinnati, Ohio, USA.
Neil E ErnstUC Health - University of Cincinnati Medical Center, Department of Pharmacy Services, Cincinnati, Ohio, USA.
Eric W MuellerUC Health - University of Cincinnati Medical Center, Department of Pharmacy Services, Cincinnati, Ohio, USA.
Charles A PeloquinInfectious Disease Pharmacokinetics Laboratory, Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-9002-7052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis causes half of acute kidney injuries in the intensive care unit (ICU). ICU patients may need continuous renal replacement therapy (CRRT), which will affect their antimicrobial exposure. We aimed to build a cefepime population pharmacokinetic (PK) model in CRRT ICU patients and perform simulations to assess target attainment. Patients who were ≥18 years old, were admitted to the ICU, and received cefepime 2 g every 8 h as a 4-h infusion while on CRRT were enrolled prospectively. Samples were collected from the predialyzer ports, postdialyzer ports, and effluent fluid at 1, 2, 3, 4, and 8 h after the first dose and at steady state. Age, sex, weight, urine output, and CRRT parameters were recorded. Pmetrics was used for population PK and simulations. The target exposure was 100% of the dosing interval during which the free beta-lactam concentration is above the MIC (

Indexed as

Continuous Renal Replacement TherapyAdolescentAnti-Bacterial AgentsCefepimeCritical IllnessFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMonte Carlo MethodRenal Replacement TherapyAnti-Bacterial AgentsCefepimecefepimeCRRTMonte Carlo simulationpopulation pharmacokinetics

Identifiers

PMID33722885
PMCPMC8316051

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.